Therapeutic effects of leuprorelin microspheres on endometriosis and uterine leiomyomata.
Uterine leiomyomata and endometriosis are two common hormone-dependent pathologies effecting women of reproductive age. Prior to the introduction of gonadotropin releasing hormone agonists (GnRHa), there was no effective medical therapy for leiomyomata, and the most effective pharmaceutical intervention for endometriosis had unacceptable side effects. Early intranasal and non-depot formulations of GnRHa were effective treatments for these diseases but patient acceptance and compliance was poor. The introduction of depot microspheres of leuprorelin (leuprolide) acetate has provided efficacious and safe medical management of both endometriosis and uterine leiomyomata which is well tolerated by most patients.